Printer Friendly

Articles from M2 Pharma (November 6, 2019)

1-15 out of 15 article(s)
Title Author Type Words
Acadia Pharmaceuticals Names Subbiah as SVP and Global Head of Medical Affairs and Chief Medical Officer. 318
Active Biotech announces presentation of new preclinical data on naptumomab estafenatox at the Society for Immunotherapy of Cancer's 34th Annual Meeting. 239
AvantGen names Mark F. Kubik as chief business officer. 136
Biodesix Sees First System-Wide Integration of Nodify XL2 Testing for Lung Nodule Management. 441
Boehringer Ingelheim and Eli Lilly to modernise present collaboration. 203
Cerevel Therapeutics Names Sulzberger to its Board of Directors. 431
IVERIC bio announces inducement grants to Abraham Scaria under Nasdaq Listing Rule 5635(c)(4). 240
Jazz Pharmaceuticals reports Q3 2019 financial results. Financial report 210
Karo Phrama reports on termination of project by Pfizer regarding ROR-gamma. 185
KORU Medical Systems achieves higher USD0.02 per diluted share for Q3 2019. 182
Melanoma Research Alliance receives USD20m in new funding for melanoma research programme. 191
Provention Bio announces Q3 2019 financial results. Financial report 199
Samsung Biologics signs long term manufacturing contract with Ichnos Sciences. 157
US FDA approves Sanofi's Fluzone High-Dose Quadrivalent for seniors. 141
X4 Pharmaceuticals Names Meisner as General Counsel. 317

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters